Eleni Gourni
Bern, BE, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
Optimizing FAPI homodimers for theranostic applications: The impact of the linker design in DOTAGA.Glu2.(FAPI)2 and DOTAGA.PEG2.Glu.(FAPI)2.
Journal: European journal of nuclear medicine and molecular imaging
Published: May 26, 2026
Homomultimeric FAP Inhibitor-Based Radioligands for Cancer Theranostics: Design Principles, Structure-Function Relationships, and Preclinical Performance.
Journal: Molecules (Basel, Switzerland)
Published: April 21, 2026
A true theranostic pair - 44/47Sc-labeled GRPR antagonist shows great promise for managing prostate and breast cancer.
Journal: European journal of nuclear medicine and molecular imaging
Published: September 05, 2025
Preclinical Evaluation of a 177Lu-Labeled Gastrin-Releasing Peptide Receptor Antagonist and Prostate Cancer Treatment with Monotherapy and in Combination with Everolimus.
Journal: ACS pharmacology & translational science
Published: July 09, 2025
Preclinical evaluation of DOTAGA.Glu.(FAPI)2 and DO3A.Glu.(FAPI)2 as theranostics with human dosimetry extrapolation to lutetium-177 and terbium-161 analogs.
Journal: European journal of nuclear medicine and molecular imaging
Published: July 08, 2025
Improved FAPI-radiopharmaceutical pharmacokinetics from the perspectives of a dose escalation study.
Improved FAPI-radiopharmaceutical pharmacokinetics from the perspectives of a dose escalation study.
Journal: European journal of nuclear medicine and molecular imaging
Published: November 01, 2024
Tailoring Fibroblast-Activation Protein Targeting for Theranostics: A Comparative Preclinical Evaluation of the 68Ga- and 177Lu-Labeled Monomeric and Dimeric Fibroblast-Activation Protein Inhibitors DOTA.SA.FAPi and DOTAGA.(SA.FAPi)2.
Journal: Molecules (Basel, Switzerland)
Published: May 17, 2024
GRPR-targeting radiotheranostics for breast cancer management.
Journal: Frontiers in medicine
Published: June 30, 2023
Translational assessment of a DATA-functionalized FAP inhibitor with facile 68Ga-labeling at room temperature.
Journal: European journal of nuclear medicine and molecular imaging
Published: January 30, 2023
In silico study on radiobiological efficacy of Ac-225 and Lu-177 for PSMA-guided radiotherapy.
Journal: Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference
Published: December 11, 2021
New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current Progress.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: September 03, 2021
Is Hypoxia a Factor Influencing PSMA-Directed Radioligand Therapy?-An In Silico Study on the Role of Chronic Hypoxia in Prostate Cancer.
Journal: Cancers
Published: May 06, 2021
Last Updated: 09/26/2026